Simultaneous determination of the brand new two-drug combination for the treatment of hepatitis C: Sofosbuvir/ledipasvir using smart spectrophotometric methods manipulating ratio spectra.
In this work, various sensitive and selective spectrophotometric methods were first introduced for the simultaneous determination of sofosbuvir and ledipasvir in their binary mixture without preliminary separation. Ledipasvir was determined simply by zero-order spectrophotometric method at its λmax=333.0nm in a linear range of 2.5-30.0μg/ml without any interference of sofosbuvir even in low or high concentrations and with mean percentage recovery of 100.05±0.632. Sofosbuvir can be quantitatively estimated by one of the following smart spectrophotometric methods based on ratio spectra developed for the resolution of the overlapped spectra of their binary mixture; ratio difference spectrophotometric method (RD) by computing the difference between the amplitudes of sofosbuvir ratio spectra at 228nm and 270nm, first derivative (DD1) of ratio spectra by measuring the sum of amplitude of trough and peak at 265nm and 277nm, respectively, ratio subtraction (RS) spectrophotometric method in which sofosbuvir can be successfully determined at its λmax=261.0nm and mean centering (MC) of ratio spectra by measuring the mean centering values at 270nm. All of the above mentioned spectrophotometric methods can estimate sofosbuvir in a linear range of 7.5-90.0μg/ml with mean percentage recoveries of 100.57±0.810, 99.92±0.759, 99.51±0.475 and 100.75±0.672, respectively. These methods were successfully applied to the analysis of their combined dosage form and bulk powder. The adopted methods were also validated as per ICH guidelines and statistically compared to an in-house HPLC method.